EDP Sciences logo
Authentification abonné
Rechercher
Menu
Accueil Tous les numéros Volume 29 / Numéro 4 (Avril 2013) Med Sci (Paris), 29 4 (2013) 425-429 Références
Accès gratuit
Numéro
Med Sci (Paris)
Volume 29, Numéro 4, Avril 2013
Page(s) 425 - 429
Section M/S Revues
DOI https://doi.org/10.1051/medsci/2013294017
Publié en ligne 26 avril 2013
  1. Alten R, Gram H, Joosten LA, et al. The human anti-IL-1 beta monoclonal antibody ACZ885 is effective in joint inflammation models in mice, in a proof-of-concept study in patients with rheumatoid arthritis. Arthritis Res Ther 2008 ; 10 : R67. [CrossRef] [PubMed] [Google Scholar]
  2. Emery P. Optimizing outcomes in patients with rheumatoid arthritis and an inadequate response to anti-TNF treatment. Rheumatology (Oxford) 2012 ; 51 : v22–v30. [CrossRef] [PubMed] [Google Scholar]
  3. Elias JA, Lee CG. IL-13 in asthma. The successful integration of lessons from mice and humans. Am J Respir Crit Care Med 2011 ; 183 : 957–958. [CrossRef] [PubMed] [Google Scholar]
  4. Sebzda E, Mariathasan S, Ohteki T, et al. Selection of the T cell repertoire. Annu Rev Immunol 1999 ; 17 : 829–874. [CrossRef] [PubMed] [Google Scholar]
  5. Josefowicz SZ, Lu LF, Rudensky AY. Regulatory T cells: mechanisms of differentiation and function. Annu Rev Immunol 2012 ; 30 : 531–564. [CrossRef] [PubMed] [Google Scholar]
  6. Goodnow CC. Balancing immunity and tolerance: deleting and tuning lymphocyte repertoires. Proc Natl Acad Sci USA 1996 ; 93 : 2264–2271. [CrossRef] [Google Scholar]
  7. Nemazee DA, Burki K. Clonal deletion of B lymphocytes in a transgenic mouse bearing anti-MHC class I antibody genes. Nature 1989 ; 337 : 562–566. [CrossRef] [PubMed] [Google Scholar]
  8. Cambier JC, Gauld SB, Merrell KT, Vilen BJ. B-cell anergy: from transgenic models to naturally occurring anergic B cells? Nat Rev Immunol 2007 ; 7 : 633–643. [CrossRef] [PubMed] [Google Scholar]
  9. Zagury D, Bernard J, Halbreich A, et al. One-year follow-up of vaccine therapy in HIV-infected immune-deficient individuals: a new strategy. J Acquir Immune Defic Syndr 1992 ; 5 : 676–681. [PubMed] [Google Scholar]
  10. Gringeri A, Musicco M, Hermans P, et al. Active anti-interferon-alpha immunization: a European-Israeli, randomized, double-blind, placebo-controlled clinical trial in 242 HIV-1-infected patients (the EURIS study). J Acquir Immune Defic Syndr Hum Retrovirol 1999 ; 20 : 358–370. [CrossRef] [PubMed] [Google Scholar]
  11. Dalum I, Jensen MR, Hindersson P, et al. Breaking of B cell tolerance toward a highly conserved self protein. J Immunol 1996 ; 157 : 4796–4804. [PubMed] [Google Scholar]
  12. Dalum I, Butler DM, Jensen MR, et al. Therapeutic antibodies elicited by immunization against TNF-alpha. Nat Biotechnol 1999 ; 17 : 666–669. [CrossRef] [PubMed] [Google Scholar]
  13. Richard M, Grencis RK, Humphreys NE, et al. Anti-IL-9 vaccination prevents worm expulsion and blood eosinophilia in Trichuris muris-infected mice. Proc Natl Acad Sci USA 2000 ; 97 : 767–772. [CrossRef] [Google Scholar]
  14. Khan WI, Richard M, Akiho H, et al. Modulation of intestinal muscle contraction by interleukin-9 (IL-9) or IL-9 neutralization: correlation with worm expulsion in murine nematode infections. Infect Immun 2003 ; 71 : 2430–2438. [CrossRef] [PubMed] [Google Scholar]
  15. Arendse B, Van Snick J, Brombacher F. IL-9 is a susceptibility factor in Leishmania major infection by promoting detrimental Th2/type 2 responses. J Immunol 2005 ; 174 : 2205–2211. [PubMed] [Google Scholar]
  16. Bizzini B, Drouet B, Zagury D, et al. Kinoids: a family of immunogens for active anticytokine immunotherapy applied to autoimmune diseases and cancer. Immunotherapy 2010 ; 2 : 347–365. [CrossRef] [PubMed] [Google Scholar]
  17. Zagury D, Le Buanec H, Mathian A, et al. IFNalpha kinoid vaccine-induced neutralizing antibodies prevent clinical manifestations in a lupus flare murine model. Proc Natl Acad Sci USA 2009 ; 106 : 5294–5299. [CrossRef] [Google Scholar]
  18. Bensussan A, Bizzini B, Pouletty P, et al. Les kinoïdes : une nouvelle génération de vaccins thérapeutiques. Med Sci (Paris) 2008 ; 24 : 306–313. [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]
  19. Uyttenhove C, Van Snick J. Development of an anti-IL-17A auto-vaccine that prevents experimental auto-immune encephalomyelitis. Eur J Immunol 2006 ; 36 : 2868–2874. [CrossRef] [PubMed] [Google Scholar]
  20. Uyttenhove C, Marillier RG, Tacchini-Cottier F, et al. Amine-reactive OVA multimers for auto-vaccination against cytokines and other mediators: perspectives illustrated for GCP-2 in L. major infection. J Leukoc Biol 2011 ; 89 : 1001–1007. [CrossRef] [PubMed] [Google Scholar]
  21. Bachmann M, Hoffmann Rorher U, Kündig TM, et al. The influence of antigen organization on B cell responsiveness. Science 1993 ; 262 : 1448–1451. [CrossRef] [PubMed] [Google Scholar]
  22. Bachmann MF, Dyer MR. Therapeutic vaccination for chronic diseases: a new class of drugs in sight. Nat Rev Drug Discov 2004 ; 3 : 81–88. [CrossRef] [PubMed] [Google Scholar]
  23. Jegerlehner A, Tissot A, Lechner F, et al. A molecular assembly system that renders antigens of choice highly repetitive for induction of protective B cell responses. Vaccine 2002 ; 20 : 3104–3112. [CrossRef] [PubMed] [Google Scholar]
  24. Sonderegger I, Rohn TA, Kurrer MO, et al. Neutralization of IL-17 by active vaccination inhibits IL-23-dependent autoimmune myocarditis. Eur J Immunol 2006 ; 36 : 2849–2856. [CrossRef] [PubMed] [Google Scholar]
  25. Hertz M, Mahalingam S, Dalum I, et al. Active vaccination against IL-5 bypasses immunological tolerance and ameliorates experimental asthma. J Immunol 2001 ; 167 : 3792–3799. [PubMed] [Google Scholar]
  26. Morimoto S, Kanno Y, Tanaka Y, et al. CD134L engagement enhances human B cell Ig production: CD154/CD40, CD70/CD27, and CD134/CD134L interactions coordinately regulate T cell-dependent B cell responses. J Immunol 2000 ; 164 : 4097–4104. [PubMed] [Google Scholar]
  27. Ito T, Wang YH, Duramad O, et al. TSLP-activated dendritic cells induce an inflammatory T helper type 2 cell response through OX40 ligand. J Exp Med 2005 ; 202 : 1213–1223. [CrossRef] [PubMed] [Google Scholar]
  28. Salek-Ardakani S, Song J, Halteman BS, et al. OX40 (CD134) controls memory T helper 2 cells that drive lung inflammation. J Exp Med 2003 ; 198 : 315–324. [CrossRef] [PubMed] [Google Scholar]
  29. Lemaire MM, Vanhaudenarde A, Nizet Y, et al. Induction of autoantibodies against mouse soluble proteins after immunization with living cells presenting the autoantigen at the cell surface in fusion with a human type 2 transmembrane protein. J Immunol Methods 2011 ; 367 : 56–62. [CrossRef] [PubMed] [Google Scholar]
  30. Uyttenhove C, Sommereyns C, Theate I, et al. Anti-IL-17A autovaccination prevents clinical and histological manifestations of experimental autoimmune encephalomyelitis. Ann NY Acad Sci 2007 ; 1110 : 330–336. [CrossRef] [Google Scholar]
  31. Verbeke H, Struyf S, Berghmans N, et al. Isotypic neutralizing antibodies against mouse GCP-2/CXCL6 inhibit melanoma growth and metastasis. Cancer Lett 2011 ; 302 : 54–62. [CrossRef] [PubMed] [Google Scholar]
  32. Le Buanec H, Bensussan A, Bagot M, et al. Active and passive anticytokine immune therapies: current status and development. Adv Immunol 2012 ; 115 : 187–227. [CrossRef] [PubMed] [Google Scholar]

Les statistiques affichées correspondent au cumul d'une part des vues des résumés de l'article et d'autre part des vues et téléchargements de l'article plein-texte (PDF, Full-HTML, ePub... selon les formats disponibles) sur la platefome Vision4Press.

Les statistiques sont disponibles avec un délai de 48 à 96 heures et sont mises à jour quotidiennement en semaine.

Le chargement des statistiques peut être long.